Suppression of Interferon Lambda Signaling by SOCS-1 Results in Their Excessive Production during Influenza Virus Infection

English version České info

Innate cytokine response provides the first line of defense against influenza virus infection. However, excessive production of cytokines appears to be critical in the pathogenesis of influenza virus. Interferon lambdas (IFN-λ) have been shown to be overproduced during influenza virus infection, but the precise pathogenic processes of IFN-λ production have yet to be characterized. In this report, we observed that influenza virus induced robust expression of IFN-λ in alveolar epithelial cells (A549) mainly through a RIG-I-dependent pathway, but IFN-λ-induced phosphorylation of the signal transducer and activator of transcription protein 1 (STAT1) was dramatically inhibited in the infected cells. Remarkably, influenza virus infection induced robust expression of suppressor of cytokine signaling-1 (SOCS-1), leading to inhibition of STAT1 activation. Interestingly, the virus-induced SOCS-1 expression was cytokine-independent at early stage of infection both in vitro and in vivo. Using transgenic mouse model and distinct approaches altering the expression of SOCS-1 or activation of STAT signaling, we demonstrated that disruption of the SOCS-1 expression or expression of constitutively active STAT1 significantly reduced the production of IFN-λ during influenza virus infection. Furthermore, we revealed that disruption of IFN-λ signaling pathway by increased SOCS-1 protein resulted in the activation of NF-κB and thereby enhanced the IFN-λ expression. Together, these data imply that suppression of IFN-λ signaling by virus-induced SOCS-1 causes an adaptive increase in IFN-λ expression by host to protect cells against the viral infection, as a consequence, leading to excessive production of IFN-λ with impaired antiviral response.

Vyšlo v časopise: Suppression of Interferon Lambda Signaling by SOCS-1 Results in Their Excessive Production during Influenza Virus Infection. PLoS Pathog 10(1): e32767. doi:10.1371/journal.ppat.1003845
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003845

Souhrn

Zdroje

1. TeijaroJR, WalshKB, CahalanS, FremgenDM, RobertsE, et al. (2011) Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146: 980–991.

2. JewellNA, ClineT, MertzSE, SmirnovSV, FlanoE, et al. (2010) Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 84: 11515–11522.

3. KumagaiY, TakeuchiO, KatoH, KumarH, MatsuiK, et al. (2007) Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 27: 240–252.

4. KobasaD, JonesSM, ShinyaK, KashJC, CoppsJ, et al. (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319–323.

5. IwasakiA, MedzhitovR (2011) A new shield for a cytokine storm. Cell 146: 861–862.

6. KellyC, KlenermanP, BarnesE (2011) Interferon lambdas: the next cytokine storm. Gut 60: 1284–1293.

7. MordsteinM, NeugebauerE, DittV, JessenB, RiegerT, et al. (2010) Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84: 5670–5677.

8. SheppardP, KindsvogelW, XuW, HendersonK, SchlutsmeyerS, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63–68.

9. KotenkoSV, GallagherG, BaurinVV, Lewis-AntesA, ShenM, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69–77.

10. IversenMB, PaludanSR (2010) Mechanisms of type III interferon expression. J Interferon Cytokine Res 30: 573–578.

11. OkabayashiT, KojimaT, MasakiT, YokotaS, ImaizumiT, et al. (2011) Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res 160: 360–366.

12. PottJ, MahlakoivT, MordsteinM, DuerrCU, MichielsT, et al. (2011) IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108: 7944–7949.

13. QiuX, GuoG, ChenK, KashiwadaM, DrukerBJ, et al. (2012) A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia 14: 547–558.

14. ZhangJG, FarleyA, NicholsonSE, WillsonTA, ZugaroLM, et al. (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A 96: 2071–2076.

15. UngureanuD, SaharinenP, JunttilaI, HiltonDJ, SilvennoinenO (2002) Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 22: 3316–3326.

16. WaibociLW, AhmedCM, MujtabaMG, FlowersLO, MartinJP, et al. (2007) Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol 178: 5058–5068.

17. PauliEK, SchmolkeM, WolffT, ViemannD, RothJ, et al. (2008) Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog 4: e1000196.

18. PothlichetJ, ChignardM, Si-TaharM (2008) Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. J Immunol 180: 2034–2038.

19. JiaD, RahbarR, ChanRW, LeeSM, ChanMC, et al. (2010) Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One 5: e13927.

20. UetaniK, HiroiM, MeguroT, OgawaH, KamisakoT, et al. (2008) Influenza A virus abrogates IFN-gamma response in respiratory epithelial cells by disruption of the Jak/Stat pathway. Eur J Immunol 38: 1559–1573.

21. BrandS, ZitzmannK, DambacherJ, BeigelF, OlszakT, et al. (2005) SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 331: 543–548.

22. WangS, LiH, ChenY, WeiH, GaoGF, et al. (2012) Transport of influenza virus neuraminidase (NA) to host cell surface is regulated by ARHGAP21 and Cdc42 proteins. J Biol Chem 287: 9804–9816.

23. WangJP, BowenGN, PaddenC, CernyA, FinbergRW, et al. (2008) Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood 112: 2028–2034.

24. BenderA, BuiLK, FeldmanMA, LarssonM, BhardwajN (1995) Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med 182: 1663–1671.

25. PichlmairA, SchulzO, TanCP, NaslundTI, LiljestromP, et al. (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314: 997–1001.

26. HornungV, EllegastJ, KimS, BrzozkaK, JungA, et al. (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science 314: 994–997.

27. KatoH, SatoS, YoneyamaM, YamamotoM, UematsuS, et al. (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19–28.

28. SommereynsC, PaulS, StaeheliP, MichielsT (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017.

29. PoatB, HazariS, ChandraPK, GunduzF, BalartLA, et al. (2010) SH2 modified STAT1 induces HLA-I expression and improves IFN-gamma signaling in IFN-alpha resistant HCV replicon cells. PLoS One 5: e13117.

30. LiddleFJ, AlvarezJV, PoliV, FrankDA (2006) Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry 45: 5599–5605.

31. OnoguchiK, YoneyamaM, TakemuraA, AkiraS, TaniguchiT, et al. (2007) Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282: 7576–7581.

32. KobasaD, TakadaA, ShinyaK, HattaM, HalfmannP, et al. (2004) Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431: 703–707.

33. GarciaCC, RussoRC, GuabirabaR, FagundesCT, PolidoroRB, et al. (2010) Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice. PLoS Pathog 6: e1001171.

34. Le GofficR, LeymarieO, ChevalierC, ReboursE, Da CostaB, et al. (2011) Transcriptomic analysis of host immune and cell death responses associated with the influenza A virus PB1-F2 protein. PLoS Pathog 7: e1002202.

35. LuD, MaY, ZhangW, BaoD, DongW, et al. (2012) Knockdown of cytochrome P450 2E1 inhibits oxidative stress and apoptosis in the cTnT(R141W) dilated cardiomyopathy transgenic mice. Hypertension 60: 81–89.

36. YangJ, WangJ, ChenK, GuoG, XiR, et al. (2013) eIF4B phosphorylation by Pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res 73: 4898–4908.

37. McKennaK, BeignonAS, BhardwajN (2005) Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 79: 17–27.

38. TakeuchiO, AkiraS (2009) Innate immunity to virus infection. Immunol Rev 227: 75–86.

39. La GrutaNL, KedzierskaK, StambasJ, DohertyPC (2007) A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 85: 85–92.

40. MarukianS, AndrusL, SheahanTP, JonesCT, CharlesED, et al. (2011) Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology 54: 1913–1923.

41. LiJ, HuS, ZhouL, YeL, WangX, et al. (2011) Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia 59: 58–67.

42. SvetlikovaD, KabatP, OhradanovaA, PastorekJ, BetakovaT (2010) Influenza A virus replication is inhibited in IFN-lambda2 and IFN-lambda3 transfected or stimulated cells. Antiviral Res 88: 329–333.

43. WangJ, Oberley-DeeganR, WangS, NikradM, FunkCJ, et al. (2009) Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection. J Immunol 182: 1296–1304.

44. KimuraA, NakaT, NakahamaT, ChinenI, MasudaK, et al. (2009) Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med 206: 2027–2035.

45. ShenH, LentschAB (2004) Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol 286: C840–847.

46. WangY, WuTR, CaiS, WelteT, ChinYE (2000) Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activation. Mol Cell Biol 20: 4505–4512.

47. AustenaaLM, CarlsenH, HollungK, BlomhoffHK, BlomhoffR (2009) Retinoic acid dampens LPS-induced NF-kappaB activity: results from human monoblasts and in vivo imaging of NF-kappaB reporter mice. J Nutr Biochem 20: 726–734.

48. KramerOH, BausD, KnauerSK, SteinS, JagerE, et al. (2006) Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 20: 473–485.

49. StrebovskyJ, WalkerP, LangR, DalpkeAH (2011) Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. FASEB J 25: 863–874.

50. DaiX, SayamaK, YamasakiK, TohyamaM, ShirakataY, et al. (2006) SOCS1-negative feedback of STAT1 activation is a key pathway in the dsRNA-induced innate immune response of human keratinocytes. J Invest Dermatol 126: 1574–1581.

51. FanK, JiaY, WangS, LiH, WuD, et al. (2012) Role of Itk signalling in the interaction between influenza A virus and T-cells. J Gen Virol 93: 987–997.

52. AhmedCM, DabelicR, WaibociLW, JagerLD, HeronLL, et al. (2009) SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system. J Virol 83: 1402–1415.

53. GuoG, QiuX, WangS, ChenY, RothmanPB, et al. (2010) Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene 29: 3845–3853.

54. ZitzmannK, BrandS, De ToniEN, BaehsS, GokeB, et al. (2007) SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 67: 5025–5032.

55. HuangFJ, SteegPS, PriceJE, ChiuWT, ChouPC, et al. (2008) Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 68: 9634–9642.

56. ShenL, Evel-KablerK, StrubeR, ChenSY (2004) Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 22: 1546–1553.

57. JiangLJ, ZhangNN, DingF, LiXY, ChenL, et al. (2011) RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc Natl Acad Sci U S A 108: 1897–1902.

58. DelaloyeJ, RogerT, Steiner-TardivelQG, Le RoyD, Knaup ReymondM, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5: e1000480.

59. ReedLJ, MuenchH (1938) A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 27: 493–497.